Study of microencapsulated fatty acid antimicrobial activity in vitro and its prevention ability of Clostridium perfringens induced necrotic enteritis in broiler chicken

Table 1 MICs and MBCs of different treatments against different strains of C. perfringens

Treatment	CP-D25^#		CP-MZ1^#		CP-C8-1^#		CP-CVCC52^#
Treatment	MIC^# (mg/mL)	MBC^# (mg/mL)	MIC^# (mg/mL)	MBC^# (mg/mL)	MIC^# (mg/mL)	MBC^# (mg/mL)	MIC^# (mg/mL)	MBC^# (mg/mL)
C8-C12-C14	0.1	0.1	0.1	0.2	0.5	1.0	0.2	0.2
C12-C14	0.00625	0.05	0.0125	0.05	0.00625	0.05	0.003125	0.05
C10-C12	0.05	0.1	0.05	0.1	0.5	0.5	0.025	0.1
Avilamycin	0.00625	0.05	Resistant	Resistant	Resistant	Resistant	0.00625	0.05

MIC minimum inhibitory concentration, MBC minimum bactericidal concentration
^#CP-D25, C. perfringens type G strains, sensitive to Avilamycin. CP-MZ1, C. perfringens type G strains, resistance to Avilamycin. CP-C8-1, C. perfringens type A strains, resistance to Avilamycin. CP-CVCC52, C. perfringens type A strains, sensitive to Avilamycin

ISSN: 1757-4749